CompletedNCT00128505
Mifepristone follow-up for recurring psychotic depression
About this title
Read the official source — NCT00128505Researchers studied Mifepristone to find out how it affected psychotic symptoms in people with depression.
Medication studyAges 18–75Multiple countries
Understand this study
What did researchers investigate?
Researchers studied Mifepristone to find out how it affected psychotic symptoms in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Sofia and 18 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 104
- Sponsor
- Corcept Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Bulgaria, Croatia, Romania, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00128505
- Official title
Show the full official title
An International, Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Sofia, Bulgaria · Varna, Bulgaria · Osijek, Croatia
8 more locations
- Rijeka, Croatia
- Split, Croatia
- Zagreb, Croatia
- Bucharest, Romania
- Târgu Mureş, Romania
- Belgrade, Serbia
- Kragujevac, Serbia
- Novi Sad, Serbia
Questions about this study
What did researchers investigate?
Researchers studied Mifepristone to find out how it affected psychotic symptoms in people with depression.
Who is behind this study?
The study sponsor is Corcept Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Mifepristone.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
